Sarepta Therapeutics, Inc.
SRPT Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$17.98
KIRA · Stoqly’s AI analyst, in plain words
- Sarepta Therapeutics, Inc. had $2.2B of revenue in fiscal 2025, up 15.6% on the year before. Over five years, revenue changed +32.4% a year on average.
- Its operating margin was −31.8%, down 43.3 pts: of every 100 in sales, about −32 is left after running the business.
- Sarepta Therapeutics, Inc. lost $713M in fiscal 2025.
- Free cash flow was −$307M in fiscal 2025, −14.0% of revenue.
- Sarepta Therapeutics, Inc. returned $25.0M to shareholders in fiscal 2025. The diluted share count fell 7.2%.
- Sarepta Therapeutics, Inc. has $111M more cash than debt.
Market cap
$1.9B
P/E
—
Revenue
$2.2B
Net income
−$713M
Free cash flow
−$307M
Operating margin
−31.8%
Sarepta Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+15.6%
Yes. Sales grew 15.6% last year.
Does it make a profit?
−32.5%
No. It lost money last year.
Does profit turn into cash?
−14.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Sarepta Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 2, 2026
- Legal name
- Sarepta Therapeutics, Inc.
- CIK
- 0000873303
Sarepta Therapeutics, Inc. · SRPT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $702M | $933M | $1.2B | $1.9B | $2.2B |
| Revenue growth | 30.0% | 32.9% | 33.3% | 53.0% | 15.6% |
| Gross margin | — | — | — | — | 98.8% |
| Operating margin | −65.5% | −57.5% | −21.5% | 11.5% | −31.8% |
| Net income | −$419M | −$703M | −$536M | $235M | −$713M |
| Net margin | −59.7% | −75.4% | −43.1% | 12.4% | −32.5% |
| Diluted EPS | −$5.15 | −$8.03 | −$5.80 | $2.34 | −$7.13 |
| Cash | |||||
| Cash from operations | −$443M | −$325M | −$501M | −$206M | −$205M |
| Capital expenditure | $38.5M | $30.8M | $76.1M | $137M | $102M |
| Free cash flow | −$482M | −$356M | −$577M | −$343M | −$307M |
| FCF margin | −68.6% | −38.2% | −46.4% | −18.0% | −14.0% |
| Share buybacks | — | — | $0.0M | $0.0M | $25.0M |
| Share count change | 4.2% | 7.7% | 5.5% | 16.8% | −7.2% |
| Debt and strength | |||||
| Cash and short-term investments | $2.1B | $2.0B | $1.7B | $1.4B | $940M |
| Debt incl. finance leases | $564M | $1.5B | $1.2B | $1.1B | $829M |
| Shareholders' equity | $928M | $385M | $859M | $1.5B | $1.1B |
| Net debt / EBITDA | — | — | — | −0.9x | — |
| Current ratio | 5.8x | 4.1x | 3.9x | 4.2x | 2.3x |
| Interest coverage | −7.2x | — | — | — | — |
| Returns and quality | |||||
| Return on capital | — | — | −50.2% | 15.0% | −53.7% |
| Return on equity | −49.6% | −107.2% | −86.2% | 19.7% | −53.5% |
| Return on tangible equity | −45.8% | −186.4% | −64.6% | 15.7% | −64.2% |
| Piotroski F-score | 2 | 2 | 4 | 5 | 4 |
| Altman Z'' | 0.6 | −1.0 | −0.7 | 1.4 | −2.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.4M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Sarepta Therapeutics, Inc. · SRPT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $17.98 a share, the company is worth $1.9B.
Source: SEC EDGAR XBRL filings (CIK 0000873303). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.